Pharmacy Pearls: Medication Highlight - Mounjaro

Pharmacy Pearls: Medication Highlight – Mounjaro

November 7th, 2022 | Pharmacy Pearls•Diabetes

In this edition of Pharmacy Pearls, you will find information about the new medication approved for treating type 2 diabetes in adults, tirzepatide (Mounjaro®). It has a novel mechanism of action as it is a dual GLP-1 and GIP agonist and has shown impressive clinical trial results in A1c reduction and weight loss. Ongoing studies, including a CV outcomes trial, will further inform its place in therapy, but it remains an exciting potential treatment option.

Cost and insurance coverage can be tricky for this agent; patients often need to have tried and failed several agents first, and even then, cost can be prohibitive. For those with commercial insurance, there is a manufacturer coupon available to reduce the cost found here.

As always, we welcome any questions or feedback you may have. Just email the Pharmacy Team.

Taking too long?

Reload document

Open in new tab

Download PDF [184.57 KB]

ABI Value	Interpretation	Recommendation
Greater than 1.4	Calcification/vessel hardening	Refer to vascular specialist
1.0 - 1.4	Normal	None
0.9 - 1.0	Acceptable	None
0.8 - 0.9	Some arterial disease	Treat risk factor
0.5 - 0.8	Moderate arterial disease	Refer to vascular specialist
Less than 0.5	Severe arterial disease	Refer to vascular specialist

Pharmacy Pearls: Medication Highlight – Mounjaro

Pharmacy Pearls: Medication Highlight – Mounjaro

GENERAL COVID-19 INFORMATION